No Picture
News

Evofem Biosciences Announces Updated Date and Time for Fireside Chat at Cantor Global Virtual Healthcare Conference

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that its virtual fireside chat at the 2020 Cantor Global Virtual Healthcare Conference will take place from 1:20 p.m. to 1:50 p.m. ET on Thursday… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

– Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery –

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote… […]

No Picture
News

Heron Therapeutics Announces Publication of Results from EPOCH 2 Follow-On Study, a Phase 2b Study of HTX-011 in Patients Undergoing Hernia Repair Surgery

– Over 90% of Hernia Repair Patients Receiving HTX-011 Required No Opioids to Manage Their Postoperative Pain Through 72 hours After Surgery –

SAN DIEGO, Sept. 16, 2020 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biote… […]

No Picture
News

Virtual reality startup and Fujitsu bring immersive drug design software to Japanese market

SAN DIEGO, Sept. 14, 2020 /PRNewswire/ — San Diego–based virtual reality (VR) startup Nanome, Inc. has entered into an agreement with Fujitsu to bring their signature product—an immersive scientific design and collaboration platform—to the Japanese… […]

No Picture
News

Neurocrine Biosciences and Voyager Therapeutics Present New Long-Term Three-Year Data Demonstrating that One-Time Treatment with an Investigational Gene Therapy Showed Sustained Improvement in Motor Function in Patients with Parkinson’s Disease

— Data for Investigational Gene Therapy Treatment NBIb-1817 (VY-AADC) Presented at the MDS Virtual Congress 2020 — NBIb-1817 Treatment Showed Sustained Improvement in Motor Function, Including Greater “On” Time without Troublesome Dyskinesia and Re… […]

No Picture
News

Targazyme Appoints Jim Caggiano as CEO

CARLSBAD, Calif., Sept. 11, 2020 /PRNewswire/ — Targazyme Inc., a late clinical-stage biopharmaceutical company developing novel fucosyltransferase enzyme technologies and products to improve clinical efficacy, safety, and cost of care outcomes for… […]

No Picture
News

Genelux Announces Oral Plenary Presentation of VIRO-15 Phase 2 Trial Data at the 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society

— Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows objective response and progression-free survival clinical benefits well exceed historical comparisons and patients’ own last prior therapy– The majority of patien… […]

No Picture
News

Genelux Announces Oral Plenary Presentation of VIRO-15 Phase 2 Trial Data at the 2020 xDigital Annual Global Meeting of the International Gynecologic Cancer Society

— Treatment with olvimulogene nanivacirepvec (Olvi-Vec)-primed immunochemotherapy shows objective response and progression-free survival clinical benefits well exceed historical comparisons and patients’ own last prior therapy– The majority of patien… […]